Characterization of tepoxalin and its related compounds by high-performance liquid chromatography/mass spectrometry

David J. Burinsky; Barbara L. Armstrong; Alan R. Oyler; Richard Dunphy

doi:10.1021/js9503035

Characterization of tepoxalin and its related compounds by high-performance liquid chromatography/mass spectrometry

David J. Burinsky, Barbara L. Armstrong, Alan R. Oyler, Richard Dunphy

Chemistry & Biochemistry

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

High-performance liquid chromatography/mass spectrometry (HPLC/MS) was used to identify and elucidate key structural characteristics of a novel dual cyclooxygenase/lipoxygenase inhibitor, tepoxalin (3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-N- methylpropanamide), its synthesis-related byproducts in bulk drug substance, and degradation products stemming from probe stability studies. Such information is needed to assist in synthesis optimization and in the preparation of stable formulations for toxicity studies and clinical trials. High-performance liquid chromatography, in conjunction with mass spectrometry (HPLC/MS) and UV photodiode array detection, can often expedite the gathering of preliminary data that contribute to several aspects of the pharmaceutical development process.

Original language	English (US)
Pages (from-to)	159-164
Number of pages	6
Journal	Journal of Pharmaceutical Sciences
Volume	85
Issue number	2
DOIs	https://doi.org/10.1021/js9503035
State	Published - Feb 1996

Publisher link

10.1021/js9503035

Find It

Find It at U of M Libraries

Cite this

@article{ab9186439e07448f9972c6f74741c43c,

title = "Characterization of tepoxalin and its related compounds by high-performance liquid chromatography/mass spectrometry",

abstract = "High-performance liquid chromatography/mass spectrometry (HPLC/MS) was used to identify and elucidate key structural characteristics of a novel dual cyclooxygenase/lipoxygenase inhibitor, tepoxalin (3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-N- methylpropanamide), its synthesis-related byproducts in bulk drug substance, and degradation products stemming from probe stability studies. Such information is needed to assist in synthesis optimization and in the preparation of stable formulations for toxicity studies and clinical trials. High-performance liquid chromatography, in conjunction with mass spectrometry (HPLC/MS) and UV photodiode array detection, can often expedite the gathering of preliminary data that contribute to several aspects of the pharmaceutical development process.",

author = "Burinsky, {David J.} and Armstrong, {Barbara L.} and Oyler, {Alan R.} and Richard Dunphy",

year = "1996",

month = feb,

doi = "10.1021/js9503035",

language = "English (US)",

volume = "85",

pages = "159--164",

journal = "Journal of Pharmaceutical Sciences",

issn = "0022-3549",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Characterization of tepoxalin and its related compounds by high-performance liquid chromatography/mass spectrometry

AU - Burinsky, David J.

AU - Armstrong, Barbara L.

AU - Oyler, Alan R.

AU - Dunphy, Richard

PY - 1996/2

Y1 - 1996/2

N2 - High-performance liquid chromatography/mass spectrometry (HPLC/MS) was used to identify and elucidate key structural characteristics of a novel dual cyclooxygenase/lipoxygenase inhibitor, tepoxalin (3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-N- methylpropanamide), its synthesis-related byproducts in bulk drug substance, and degradation products stemming from probe stability studies. Such information is needed to assist in synthesis optimization and in the preparation of stable formulations for toxicity studies and clinical trials. High-performance liquid chromatography, in conjunction with mass spectrometry (HPLC/MS) and UV photodiode array detection, can often expedite the gathering of preliminary data that contribute to several aspects of the pharmaceutical development process.

AB - High-performance liquid chromatography/mass spectrometry (HPLC/MS) was used to identify and elucidate key structural characteristics of a novel dual cyclooxygenase/lipoxygenase inhibitor, tepoxalin (3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-N- methylpropanamide), its synthesis-related byproducts in bulk drug substance, and degradation products stemming from probe stability studies. Such information is needed to assist in synthesis optimization and in the preparation of stable formulations for toxicity studies and clinical trials. High-performance liquid chromatography, in conjunction with mass spectrometry (HPLC/MS) and UV photodiode array detection, can often expedite the gathering of preliminary data that contribute to several aspects of the pharmaceutical development process.

UR - http://www.scopus.com/inward/record.url?scp=0030025369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030025369&partnerID=8YFLogxK

U2 - 10.1021/js9503035

DO - 10.1021/js9503035

M3 - Article

C2 - 8683441

AN - SCOPUS:0030025369

SN - 0022-3549

VL - 85

SP - 159

EP - 164

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

IS - 2

ER -

Characterization of tepoxalin and its related compounds by high-performance liquid chromatography/mass spectrometry

Abstract

Publisher link

Find It

Other files and links

Fingerprint

Cite this